Webcast must be viewed in its entirety to claim credit.
This activity is supported by an educational grant from Salix Pharmaceuticals, Inc. and provided by the Chronic Liver Disease Foundation.
Statement of Need / Program Overview
The International Liver Congress™ is the biggest event in the EASL educational calendar and will be held on April 23-26, 2015. Many US healthcare providers are unable to attend this international conference held in Vienna, Austria. In order to assure they are informed of the most important advances, this webcast is designed to summarize key data and put it in perspective for the US audience. After participating in this activity, participants will be better prepared to integrate the most recent advances in the management of patients with cirrhosis.
This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, primary care physicians, physician assistants, nurse practitioners, registered nurses and pharmacists involved in the care of patients with chronic liver disease.
Upon completion of this activity, participants should be better able to:
Describe evolving patient management and treatment strategies for patients with cirrhosis
Integrate advances in therapeutic and diagnostic modalities into their clinical practices in order to maximize patient outcomes
Purdue University College of Pharmacy designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Accreditation Statement- Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for .75 contact hours.
Pharmacist Accreditation Statement – Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-15-049-H01-P, .75 contact hours (.075 CEU).
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University School of Pharmacy and the Chronic Liver Disease Foundation (CLDF). Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Faculty, Staff and Reviewer Disclosure Statement:
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Additional planning committee, reviewer and Focus medical Communications and Purdue University staff have no relationships to disclose.
Dr. Nancy Reau is a Consultant and on the Speaker's Bureau for Gilead, AbbVie, Janssen, BMS, Merck and Salix Pharmaceuticals. She has also received Grants and Research Support from Gilead, AbbVie, BI, BMS, Merck, Janssen and Hyperion.
Dr. Laura Kulik is a Consultant for Blueprint Medicines and is on the Advisory Board for both Gilead and AbbVie.